vs
QuidelOrtho Corp（QDEL）与奇富科技（QFIN）财务数据对比。点击上方公司名可切换其他公司
奇富科技的季度营收约是QuidelOrtho Corp的1.0倍（$731.2M vs $699.9M），奇富科技净利率更高（27.5% vs -104.7%，领先132.2%），过去两年奇富科技的营收复合增速更高（16.4% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
奇富科技（原360数科）是中国头部金融科技企业，主要为持牌金融机构提供智能风控、信贷技术解决方案，服务广大个人消费者及中小微企业，依托大数据、人工智能技术提升金融服务的普惠性与运营效率。
QDEL vs QFIN — 直观对比
营收规模更大
QFIN
是对方的1.0倍
$699.9M
净利率更高
QFIN
高出132.2%
-104.7%
两年增速更快
QFIN
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $731.2M |
| 净利润 | $-733.0M | $201.2M |
| 毛利率 | — | — |
| 营业利润率 | -100.7% | 32.7% |
| 净利率 | -104.7% | 27.5% |
| 营收同比 | -3.7% | — |
| 净利润同比 | -3583.4% | — |
| 每股收益（稀释后） | $-10.78 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELQFIN
| Q3 25 | $699.9M | $731.2M | ||
| Q2 25 | $613.9M | $728.1M | ||
| Q1 25 | $692.8M | $646.4M | ||
| Q4 24 | $707.8M | — | ||
| Q3 24 | $727.1M | $622.7M | ||
| Q2 24 | $637.0M | $572.4M | ||
| Q1 24 | $711.0M | $575.2M | ||
| Q4 23 | $742.6M | — |
净利润QDELQFIN
| Q3 25 | $-733.0M | $201.2M | ||
| Q2 25 | $-255.4M | $241.6M | ||
| Q1 25 | $-12.7M | $247.6M | ||
| Q4 24 | $-178.4M | — | ||
| Q3 24 | $-19.9M | $256.3M | ||
| Q2 24 | $-147.7M | $189.4M | ||
| Q1 24 | $-1.7B | $160.7M | ||
| Q4 23 | $7.0M | — |
营业利润率QDELQFIN
| Q3 25 | -100.7% | 32.7% | ||
| Q2 25 | -29.4% | 41.0% | ||
| Q1 25 | 4.7% | 42.1% | ||
| Q4 24 | -14.2% | — | ||
| Q3 24 | 2.1% | 52.4% | ||
| Q2 24 | -18.4% | 47.7% | ||
| Q1 24 | -247.3% | 32.8% | ||
| Q4 23 | 5.4% | — |
净利率QDELQFIN
| Q3 25 | -104.7% | 27.5% | ||
| Q2 25 | -41.6% | 33.2% | ||
| Q1 25 | -1.8% | 38.3% | ||
| Q4 24 | -25.2% | — | ||
| Q3 24 | -2.7% | 41.2% | ||
| Q2 24 | -23.2% | 33.1% | ||
| Q1 24 | -239.9% | 27.9% | ||
| Q4 23 | 0.9% | — |
每股收益（稀释后）QDELQFIN
| Q3 25 | $-10.78 | — | ||
| Q2 25 | $-3.77 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $-2.54 | — | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $-2.20 | — | ||
| Q1 24 | $-25.50 | — | ||
| Q4 23 | $0.11 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $6.5B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $24.3B |
| 总资产 | $5.7B | $61.4B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELQFIN
| Q3 25 | $98.1M | $6.5B | ||
| Q2 25 | $151.7M | $5.3B | ||
| Q1 25 | $127.1M | $8.6B | ||
| Q4 24 | $98.3M | — | ||
| Q3 24 | $143.7M | $4.3B | ||
| Q2 24 | $107.0M | $6.3B | ||
| Q1 24 | $78.5M | $5.3B | ||
| Q4 23 | $167.3M | — |
总债务QDELQFIN
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — | ||
| Q4 23 | $2.3B | — |
股东权益QDELQFIN
| Q3 25 | $2.0B | $24.3B | ||
| Q2 25 | $2.8B | $24.1B | ||
| Q1 25 | $3.0B | $23.1B | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.2B | $22.9B | ||
| Q2 24 | $3.2B | $22.6B | ||
| Q1 24 | $3.3B | $22.1B | ||
| Q4 23 | $5.0B | — |
总资产QDELQFIN
| Q3 25 | $5.7B | $61.4B | ||
| Q2 25 | $6.4B | $59.8B | ||
| Q1 25 | $6.5B | $55.6B | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $6.8B | $47.0B | ||
| Q2 24 | $6.7B | $47.0B | ||
| Q1 24 | $6.7B | $47.4B | ||
| Q4 23 | $8.6B | — |
负债/权益比QDELQFIN
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — | ||
| Q4 23 | 0.45× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $351.4M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | — |
| 自由现金流率自由现金流/营收 | -13.5% | — |
| 资本支出强度资本支出/营收 | 7.0% | — |
| 现金转化率经营现金流/净利润 | — | 1.75× |
| 过去12个月自由现金流最近4个季度 | $-153.1M | — |
8季度趋势，按日历期对齐
经营现金流QDELQFIN
| Q3 25 | $-45.5M | $351.4M | ||
| Q2 25 | $-46.8M | $366.0M | ||
| Q1 25 | $65.6M | $386.6M | ||
| Q4 24 | $63.7M | — | ||
| Q3 24 | $117.9M | $338.0M | ||
| Q2 24 | $-97.9M | $269.9M | ||
| Q1 24 | $-700.0K | $271.2M | ||
| Q4 23 | $80.4M | — |
自由现金流QDELQFIN
| Q3 25 | $-94.7M | — | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $71.4M | — | ||
| Q2 24 | $-133.2M | — | ||
| Q1 24 | $-66.8M | — | ||
| Q4 23 | $31.8M | — |
自由现金流率QDELQFIN
| Q3 25 | -13.5% | — | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | -20.9% | — | ||
| Q1 24 | -9.4% | — | ||
| Q4 23 | 4.3% | — |
资本支出强度QDELQFIN
| Q3 25 | 7.0% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 9.3% | — | ||
| Q4 23 | 6.5% | — |
现金转化率QDELQFIN
| Q3 25 | — | 1.75× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.43× | ||
| Q1 24 | — | 1.69× | ||
| Q4 23 | 11.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
QFIN
暂无分部数据
